ESH ALL 2021 | Updates on ponatinib plus venetoclax for R/R Ph+ ALL
Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares the results of a Phase I/II study (NCT03576547) of combined ponatinib, venetoclax, and dexamethasone in relapsed/refractory (R/R) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Pre-clinical studies have shown synergy of the combination, and Dr Short highlights that the regimen is entirely oral. So far, the results suggest that the chemotherapy-free regimen is safe and shows promising efficacy with durable responses in a heavily pretreated population. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.
Disclosures
Consulting fees from AstraZeneca, NGMBio, Jazz Pharmaceuticals.
Research funding from Takeda Oncology and Astellas Pharma Inc.
Honoraria from Amgen and Novartis.
